Belpointe Asset Management LLC Bei Gene, Ltd. Transaction History

Belpointe Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$125.51 - $229.3 $3,137 - $5,732	25 New	25 $5,000
Q4 2018 Mar 06, 2019	SELL	$107.01 - $175.15 $1.71 Million - $2.8 Million	-15,998 Closed	0 $0
Q3 2018 Nov 23, 2018	BUY	$152.62 - $189.66 $1.85 Million - $2.3 Million	12,138 Added 314.46%	15,998 $2.76 Million
Q2 2018 Aug 06, 2018	BUY	$152.5 - $216.77 $12,352 - $17,558	81 Added 2.14%	3,860 $593,000
Q1 2018 Aug 06, 2018	SELL	$97.41 - $177.22 $1.18 Million - $2.15 Million	-12,129 Reduced 76.24%	3,779 $635,000
Q4 2017 Feb 15, 2018	BUY	$79.6 - $114.73 $3,184 - $4,589	40 Added 0.25%	15,908 $1.56 Million
Q3 2017 Nov 16, 2017	BUY	$66.19 - $103.46 $1.05 Million - $1.64 Million	15,868	15,868 $1.64 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.